Search

Author/Creator Tai, F.

3. GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. (June 2017)

Authors:
Schuster, S.J.; Bishop, M.R.; Tam, C.; Waller, E.K.; Borchmann, P.; Mcguirk, J.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Holte, H.; Anak, O.; Pacaud, L.; Awasthi, R.; Tai, F.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT. (23rd June 2022)

Authors:
Al-Samkari, H.; Grace, R. F.; Glenthøj, A.; Andres, O.; Barcellini, W.; Galactéros, F.; Kuo, K. H. M.; Layton, D. M.; Morado Arias, M.; Viprakasit, V.; Dong, Y.; Tai, F.; Grekas, L.; Khoja, K.; Gheuens, S.; McGee, B.; Porter, J. B.; van Beers, E. J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1425
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY. (23rd June 2022)

Authors:
Barcellini, W.; Grace, R. F.; Al-Samkari, H.; Glenthøj, A.; Rothman, J. A.; Morado Arias, M.; Layton, D. M.; Andres, O.; DiBacco, M.; Hawkins, P.; Judge, M. P.; Tai, F.; Morales-Arias, J.; Beynon, V.; van Beers, E. J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1429
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗